BACKGROUND: Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both US and European Commission regulatory agencies for clinical use, extends survival of patients with metastatic renal-cell carcinoma and gastrointestinal stromal tumours, but concerns have arisen about its cardiac safety. We therefore assessed the cardiovascular risk associated with sunitinib in patients with metastatic gastrointestinal stromal tumours. METHODS: We retrospectively reviewed all cardiovascular events in 75 patients with imatinib-resistant, metastatic, gastrointestinal stromal tumours who had been enrolled in a phase I/II trial investigating the efficacy of sunitinib. The composite cardiovascular endpoint was cardiac death, myocardial infarction, and congestive heart failure. We also examined sunitinib's effects on left ventricular ejection fraction (LVEF) and blood pressure. We investigated potential mechanisms of sunitinib-associated cardiac effects by studies in isolated rat cardi
%0 Journal Article
%1 Chu.2007
%A Chu, T. F.
%A Rupnick, M. A.
%A Kerkela, R.
%A Dallabrida, S. M.
%A Zurakowski, D.
%A Nguyen, L.
%A Woulfe, K.
%A Pravda, E.
%A Cassiola, F.
%A Desai, J.
%A George, S.
%A Morgan, J. A.
%A Harris, D. M.
%A Ismail, N. S.
%A Chen, J. H.
%A Schoen, F. J.
%A van den Abbeele, A. D.
%A Demetri, G. D.
%A Force, T.
%A Chen, M. H.
%D 2007
%J Lancet
%K & Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use
%N 9604
%P 2011-2019
%T Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
%U PM:18083403
%V 370
%X BACKGROUND: Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both US and European Commission regulatory agencies for clinical use, extends survival of patients with metastatic renal-cell carcinoma and gastrointestinal stromal tumours, but concerns have arisen about its cardiac safety. We therefore assessed the cardiovascular risk associated with sunitinib in patients with metastatic gastrointestinal stromal tumours. METHODS: We retrospectively reviewed all cardiovascular events in 75 patients with imatinib-resistant, metastatic, gastrointestinal stromal tumours who had been enrolled in a phase I/II trial investigating the efficacy of sunitinib. The composite cardiovascular endpoint was cardiac death, myocardial infarction, and congestive heart failure. We also examined sunitinib's effects on left ventricular ejection fraction (LVEF) and blood pressure. We investigated potential mechanisms of sunitinib-associated cardiac effects by studies in isolated rat cardi
@article{Chu.2007,
abstract = {BACKGROUND: Sunitinib, a multitargeted tyrosine-kinase inhibitor, which is approved by both US and European Commission regulatory agencies for clinical use, extends survival of patients with metastatic renal-cell carcinoma and gastrointestinal stromal tumours, but concerns have arisen about its cardiac safety. We therefore assessed the cardiovascular risk associated with sunitinib in patients with metastatic gastrointestinal stromal tumours. METHODS: We retrospectively reviewed all cardiovascular events in 75 patients with imatinib-resistant, metastatic, gastrointestinal stromal tumours who had been enrolled in a phase I/II trial investigating the efficacy of sunitinib. The composite cardiovascular endpoint was cardiac death, myocardial infarction, and congestive heart failure. We also examined sunitinib's effects on left ventricular ejection fraction (LVEF) and blood pressure. We investigated potential mechanisms of sunitinib-associated cardiac effects by studies in isolated rat cardi},
added-at = {2010-02-05T11:28:39.000+0100},
author = {Chu, T. F. and Rupnick, M. A. and Kerkela, R. and Dallabrida, S. M. and Zurakowski, D. and Nguyen, L. and Woulfe, K. and Pravda, E. and Cassiola, F. and Desai, J. and George, S. and Morgan, J. A. and Harris, D. M. and Ismail, N. S. and Chen, J. H. and Schoen, F. J. and van den Abbeele, A. D. and Demetri, G. D. and Force, T. and Chen, M. H.},
biburl = {https://www.bibsonomy.org/bibtex/2506ad4630500172729537a9ce24caf9c/kanefendt},
interhash = {fddf75bc1db57666c3c162c421922b63},
intrahash = {506ad4630500172729537a9ce24caf9c},
journal = {Lancet},
keywords = {& Aged Agents Animals Antineoplastic Arteries Artery Blood Carcinoma Coronary Disease Failure Female Gastrointestinal Heart Humans Hypertension Indoles Kinase Kinases Male Mice Middle Multicenter Pressure Protein-Tyrosine Pyrroles Rats Research Retrospective Safety Stroke Stromal Studies Topic Tumors Tyrosine Volume adverse antagonists as blood chemically drug effects induced inhibitors methods therapeutic therapy toxicity use},
number = 9604,
pages = {2011-2019},
timestamp = {2010-02-05T11:28:56.000+0100},
title = {Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib},
url = {PM:18083403},
volume = 370,
year = 2007
}